Mini P Sajan1, Robert A Ivey2, Robert V Farese3. 1. Research and Internal Medicine Services of the James A. Haley VA Medical Center, Tampa, FL; Department of Internal Medicine, University of South Florida College of Medicine, Tampa, FL. 2. Research and Internal Medicine Services of the James A. Haley VA Medical Center, Tampa, FL. 3. Research and Internal Medicine Services of the James A. Haley VA Medical Center, Tampa, FL; Department of Internal Medicine, University of South Florida College of Medicine, Tampa, FL. Electronic address: rfarese@health.usf.edu.
Abstract
Information on insulin resistance in human liver is limited. In mouse diet-induced obesity (DIO), hepatic insulin resistance initially involves: lipid+insulin-induced activation of atypical protein kinase C (aPKC); elevated Akt activity/activation but selective impairment of compartmentalized Akt-dependent FoxO1 phosphorylation; and increases in gluconeogenic and lipogenic enzymes. In advanced stages, e.g., in hepatocytes of type 2 diabetes (T2D) humans, insulin activation of insulin receptor substrate-1(IRS-1) and Akt fails, further increasing FoxO1-dependent gluconeogenic/lipogenic enzyme expression. Increases in hepatic PGC-1α also figure prominently, but uncertainly, in this scheme. Here, we examined signaling factors in liver samples harvested from human transplant donors with increasing BMI, 20→25→30→35→40→45. We found, relative to lean (BMI=20-25) humans, obese (BMI>30) humans had all abnormalities seen in early mouse DIO, but, surprisingly, at all elevated BMI levels, had decreased insulin receptor-1 (IRS-1) levels, decreased Akt activity, and increased expression/abundance of aPKC-ι and PGC-1α. Moreover, with increasing BMI, there were: progressive increases in aPKC activity and PKC-ι expression/abundance; progressive decreases in IRS-1 levels, Akt activity and FoxO1 phosphorylation; progressive increases in expression/abundance of PGC-1α; and progressive increases in gluconeogenic and lipogenic enzymes. Remarkably, all abnormalities reached T2D levels at higher BMI levels. Most importantly, both "early" and advanced abnormalities were largely reversed by 24-hour treatment of T2D hepatocytes with aPKC inhibitor. We conclude: hepatic insulin resistance in human obesity is: advanced; BMI-correlated; and sequentially involves increased aPKC-activating ceramide; increased aPKC levels and activity; decreases in IRS-1 levels, Akt activity, and FoxO1 phosphorylation; and increases in expression/abundance of PGC-1α and gluconeogenic and lipogenic genes. Published by Elsevier Inc.
Information on insulin resistance in pan class="Species">human liver is limited. In mouse diet-induced obesity (DIO), hepatic insulin resistance initially involves: lipid+insulin-induced activation of atypical protein kinase C (aPKC); elevated Akt activity/activation but selective impairment of compartmentalized Akt-dependent FoxO1 phosphorylation; and increases in gluconeogenic and lipogenic enzymes. In advanced stages, e.g., in hepatocytes of type 2 diabetes (T2D) humans, insulin activation of insulin receptor substrate-1(IRS-1) and Akt fails, further increasing FoxO1-dependent gluconeogenic/lipogenic enzyme expression. Increases in hepatic PGC-1α also figure prominently, but uncertainly, in this scheme. Here, we examined signaling factors in liver samples harvested from human transplant donors with increasing BMI, 20→25→30→35→40→45. We found, relative to lean (BMI=20-25) humans, obese (BMI>30) humans had all abnormalities seen in early mouseDIO, but, surprisingly, at all elevated BMI levels, had decreased insulin receptor-1 (IRS-1) levels, decreased Akt activity, and increased expression/abundance of aPKC-ι and PGC-1α. Moreover, with increasing BMI, there were: progressive increases in aPKC activity and PKC-ι expression/abundance; progressive decreases in IRS-1 levels, Akt activity and FoxO1 phosphorylation; progressive increases in expression/abundance of PGC-1α; and progressive increases in gluconeogenic and lipogenic enzymes. Remarkably, all abnormalities reached T2D levels at higher BMI levels. Most importantly, both "early" and advanced abnormalities were largely reversed by 24-hour treatment of T2D hepatocytes with aPKC inhibitor. We conclude: hepatic insulin resistance in humanobesity is: advanced; BMI-correlated; and sequentially involves increased aPKC-activating ceramide; increased aPKC levels and activity; decreases in IRS-1 levels, Akt activity, and FoxO1 phosphorylation; and increases in expression/abundance of PGC-1α and gluconeogenic and lipogenic genes. Published by Elsevier Inc.
Authors: Thomas K Felder; Selma M Soyal; Hannes Oberkofler; Penelope Hahne; Simon Auer; Richard Weiss; Gabriele Gadermaier; Karl Miller; Franz Krempler; Harald Esterbauer; Wolfgang Patsch Journal: J Biol Chem Date: 2011-10-18 Impact factor: 5.157
Authors: Thorsten Fritzius; Gabriela Burkard; Elvira Haas; Jochen Heinrich; Marc Schweneker; Magnus Bosse; Sven Zimmermann; Alexander D Frey; Antje Caelers; Andre S Bachmann; Karin Moelling Journal: Biochem J Date: 2006-10-01 Impact factor: 3.857
Authors: Agneta L Sunehag; Gianna Toffolo; Marco Campioni; Dennis M Bier; Morey W Haymond Journal: J Clin Endocrinol Metab Date: 2005-05-31 Impact factor: 5.958
Authors: Cullen M Taniguchi; Tatsuya Kondo; Mini Sajan; Ji Luo; Roderick Bronson; Tomoichiro Asano; Robert Farese; Lewis C Cantley; C Ronald Kahn Journal: Cell Metab Date: 2006-05 Impact factor: 27.287
Authors: M L Standaert; G Bandyopadhyay; L Perez; D Price; L Galloway; A Poklepovic; M P Sajan; V Cenni; A Sirri; J Moscat; A Toker; R V Farese Journal: J Biol Chem Date: 1999-09-03 Impact factor: 5.157
Authors: Mini Sajan; Barbara Hansen; Robert Ivey; Joshua Sajan; Csilla Ari; Shijie Song; Ursula Braun; Michael Leitges; Margaret Farese-Higgs; Robert V Farese Journal: Diabetes Date: 2016-02-19 Impact factor: 9.461
Authors: Marie S A Palmnäs; Karen A Kopciuk; Rustem A Shaykhutdinov; Paula J Robson; Diane Mignault; Rémi Rabasa-Lhoret; Hans J Vogel; Ilona Csizmadi Journal: Sci Rep Date: 2018-02-19 Impact factor: 4.379